First launch for Daiichi Sankyo’s oncolytic virus Delytact in Japan
pharmaphorum
NOVEMBER 1, 2021
Approval was based on data from a single-arm phase 2 trial which showed that Delytact improved chances of survival at one year in patients with residual or recurrent glioblastoma previously treated with radiotherapy and temozolomide chemotherapy who residual or recurrent disease.
Let's personalize your content